• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Vicarious Surgical Announces President Transition to Board Member Role

    3/24/25 4:05:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks.

    As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical's manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel realignment, streamlined business processes, and formalized workflows and standardized procedures in order to position the Company for its next phase of growth.

    "Under Randy's leadership as President, Vicarious Surgical has made significant strides in building a strong foundation for future growth," said Adam Sachs, Co-founder and Chief Executive Officer. "We are incredibly grateful for his dedication and are delighted that he will continue to contribute his invaluable expertise and strategic vision as a member of our Board of Directors. This transition allows us to retain his insights while evolving our leadership structure to best serve the Company's strategic and capital needs."

    Mr. Clark stated, "I want to express my sincere gratitude to the Vicarious Surgical team and Board. I am incredibly proud of what we have accomplished together, and for that, Vicarious Surgical is now exceptionally well-positioned to execute its strategy and achieve its milestones. It's precisely because of this strong foundation that I feel comfortable transitioning to a new role, knowing I'll remain a part of the Vicarious Surgical journey, supporting the Company in a different capacity as we move forward."

    About Vicarious Surgical

    Founded in 2014, Vicarious Surgical is a next-generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical's product and service development activities; the potential attributes and benefits of Vicarious Surgical's product candidates and services; Vicarious Surgical's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical's ability to identify, in-license or acquire additional technology; Vicarious Surgical's ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical's ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical's financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical's business, financial condition and results of operations; Vicarious Surgical's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical's filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250324187770/en/

    Investor Contact

    Kaitlyn Brosco

    Vicarious Surgical

    [email protected]



    Media Inquiries

    [email protected]

    Get the next $RBOT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD

      RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company's Board of Directors, effective May 22, 2025. "We are delighted to welcome Dr. Carr-Brendel to Glucotrack's Board of Directors," said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. "With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monito

      5/28/25 8:30:00 AM ET
      $GCTK
      $RBOT
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Announces New Collaboration with UMass Memorial Medical Center

      Vicarious Surgical Inc. (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed an agreement with UMass Memorial Medical Center intended to support adoption and utilization of its robotic system through enhanced perioperative practices, surgeon education and other engagement strategies. UMass Memorial Medical Center, the flagship academic medical center of UMass Memorial Health, is the largest not-for-profit hospital in Central Massachusetts with 826 licensed beds and the clinical partner of the University of Massachusetts Chan Medical School. UMass Memorial Health is committed to prov

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    SEC Filings

    See more
    • Vicarious Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vicarious Surgical Inc. (0001812173) (Filer)

      5/12/25 7:47:13 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Vicarious Surgical Inc.

      10-Q - Vicarious Surgical Inc. (0001812173) (Filer)

      5/12/25 5:00:42 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by Vicarious Surgical Inc.

      144 - Vicarious Surgical Inc. (0001812173) (Subject)

      5/1/25 4:48:24 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

      Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

      3/13/25 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

      1/29/24 8:30:00 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Announces Changes to Board of Directors

      Victoria Carr-Brendel, Ph.D. Elected to Board of Directors Tech-Focused Venture Capitalist Phil Liang to Resign Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company"), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. "On behalf of the board, I'd like to thank Phil for his critical guidance and expertise as Vicari

      1/23/23 4:10:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vicarious Surgical downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

      3/4/22 4:51:18 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Credit Suisse initiated coverage on Vicarious Surgical with a new price target

      Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

      1/7/22 7:09:02 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

      Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

      12/7/21 7:31:51 AM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      2/13/24 4:36:42 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/15/23 10:28:36 AM ET
      $RBOT
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

      SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

      8/9/23 5:10:57 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Financials

    Live finance-specific insights

    See more
    • Vicarious Surgical Reports First Quarter 2025 Financial Results

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the first quarter ended March 31, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, May 12, 2025. "Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet - our first clinical patients. 2025 will be the year Vicarious Surgical evolves into a clinical-stage company and demonstrates the immense value of o

      5/12/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical to Report First Quarter 2025 Financial Results on May 12, 2025

      Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the first quarter ended March 31, 2025 after the market closes on Monday, May 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 316641. A live and archived webcast of the event will be available at https://investor.v

      4/28/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Vicarious Surgical Reports Fourth Quarter and Full Year 2024 Financial Results

      Version 1.0 System Integration Complete; Progressing Towards First Clinical Use Achieved 2024 Cash Burn Guidance; Sets 2025 Cash Burn Guidance of $50 Million Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter and full year ended December 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, March 17, 2025. "2024 was a pivotal year of progress for Vicarious Surgical, as we expanded our strategic hospital partnerships with LSU Health New Orleans, Temple Health, and Univers

      3/17/25 4:05:00 PM ET
      $RBOT
      Industrial Specialties
      Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Khalifa Sammy sold $1,733 worth of shares (239 units at $7.25), decreasing direct ownership by 0.67% to 35,630 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/4/25 2:16:21 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • CEO Sachs Adam David sold $3,343 worth of shares (463 units at $7.22), decreasing direct ownership by 0.90% to 50,723 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      6/4/25 2:16:05 PM ET
      $RBOT
      Industrial Specialties
      Health Care
    • Chief Technology Officer Khalifa Sammy sold $4,912 worth of shares (653 units at $7.52), decreasing direct ownership by 2% to 35,869 units (SEC Form 4)

      4 - Vicarious Surgical Inc. (0001812173) (Issuer)

      5/21/25 1:19:38 PM ET
      $RBOT
      Industrial Specialties
      Health Care